Clinical trials: Endometrial Cancer Stage II
Endometrial Cancer
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
The goal of this clinical research study is to learn if the combination of RAD001 (everolimus) and Femara (letrozole) can help to control recurrent or progressive endometrial cancer.
- Trial name
- NCT01068249
- Testing
- Letrozole, RAD001 (Everolimus)
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Gynecologic Cancer, Colorectal Cancer
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05194735
- Testing
- Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Alaunos Therapeutics
Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma
Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer
This phase II trial studies how well temsirolimus works in treating patients with endometrial cancer that has spread to other parts of the body or has spread from where it started to nearby tissue or lymph nodes and has come back…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Cell Carcinoma, Endometrial Clear Cell Carcinoma, Endometrial Papillary Serous Carcinoma
- Trial name
- NCT00072176
- Testing
- temsirolimus, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Uterine Cervical Cancer, Endometrial Cancer
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
This study is a phase II clinical and pharmacokinetic trial of PM00104 (Zalypsis®) in patients with advanced and/or metastatic endometrial or cervical cancer previously treated with one line of systemic chemotherapy to evaluate…
- Trial name
- NCT00900562
- Testing
- Zalypsis ( PM00104)
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- PharmaMar
Endometrial Cancer
The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer
This trial will explore the safety and efficacy of BN83485 compared to Megestrol Acetate (MA) on progression free survival (PFS) in post menopausal patients with endometrial cancer.
- Trial name
- NCT00910091
- Testing
- BN83495, Megestrol Acetate (MA)
- Where
- 54 sites in Belgium, Czechia and 10 more
- Volunteers
- 73 people
- Sponsor
- Ipsen
Endometrial Cancer
Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00470067
- Testing
- carboplatin, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
This randomized phase II/III trial studies how well paclitaxel, carboplatin, and metformin hydrochloride works and compares it to paclitaxel, carboplatin, and placebo in treating patients with endometrial cancer that is stage…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma
- Trial name
- NCT02065687
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Metformin Hydrochloride
- Where
- 431 sites in United States
- Volunteers
- 469 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Cancer
Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00258362
- Testing
- carboplatin, docetaxel, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Recurrent Endometrial Carcinoma
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial is studying the side effects and how well VEGF Trap works in treating patients with recurrent or persistent endometrial cancer.
- Trial name
- NCT00462826
- Testing
- ziv-aflibercept
- Where
- 67 sites in United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Endometrial Carcinoma
Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial is studying how well lapatinib works in treating patients with recurrent or persistent endometrial cancer. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth
- Trial name
- NCT00096447
- Testing
- lapatinib ditosylate
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer, Endometrial Adenocarcinoma
Pembro/Carbo/Taxol in Endometrial Cancer
This is a single-arm, open-label, multi-center phase II study for subjects with measurable advanced or recurrent endometrial cancer using pembrolizumab in combination with carboplatin and paclitaxel chemotherapy.
- Trial name
- NCT02549209
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Daniela Matei, MD
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
This phase II trial studies the side effects and how well trebananib works in treating patients with persistent or recurrent endometrial cancer.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
- Trial name
- NCT01210222
- Testing
- Trebananib
- Where
- 33 sites in United States
- Volunteers
- 35 people
- Sponsor
- Gynecologic Oncology Group
Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
This phase II trial studies how well enzalutamide, carboplatin, and paclitaxel work in treating patients with endometrioid endometrial cancer that is stage III-IV or has come back.
- Conditions
- Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7
- Trial name
- NCT02684227
- Testing
- Carboplatin, Enzalutamide, Laboratory Biomarker Analysis
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Cancer
Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer
The goal of this clinical research study is to learn if cetuximab can help to control the disease in patients who have recurrent endometrial cancer. Primary Objective: 1.
- Trial name
- NCT00392769
- Testing
- Cetuximab
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- M.D. Anderson Cancer Center
Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma
Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
This phase I/II trial is studying how well fludeoxyglucose F 18 PET scan, CT scan, and ferumoxtran-10 MRI scan finds lymph node metastasis before undergoing chemotherapy and radiation therapy in patients with locally advanced…
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma
- Trial name
- NCT00416455
- Testing
- fludeoxyglucose F 18, positron emission tomography, computed tomography
- Where
- 33 sites in United States, Canada and 2 more
- Volunteers
- 384 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
To assess the objective response rate (ORR: complete response + partial response [CR+ PR]) of E7080 in subjects with unresectable endometrial cancer and disease progression following platinum-based, first-line chemotherapy. .
- Trial name
- NCT01111461
- Testing
- Lenvatinib
- Where
- 78 sites in United States, Belgium and 6 more
- Volunteers
- 133 people
- Sponsor
- Eisai Inc.
Endometrial Cancer Recurrent
ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer
This was a Phase 2, Simon two-stage, non-randomized, open-label, 2-arm trial of dordaviprone (ONC201) in women with metastatic or recurrent Type II endometrial cancer who failed at least 1 prior chemotherapy regimen.
- Trial name
- NCT03485729
- Testing
- Dordaviprone (ONC201)
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Jazz Pharmaceuticals
Metastatic Cancer, Endometrium Cancer
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
It's propose this pilot phase 2 study to explore the combination therapy of futibatinib with pembrolizumab in patients with metastatic microsatellite stable (MSS) endometrial carcinoma to provide a well-tolerated regimen for…
- Conditions
- Metastatic Cancer, Endometrium Cancer, Endometrial Carcinoma
- Trial name
- NCT05036681
- Testing
- Futibatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
Background: Cancers of the female reproductive organs often come back after treatment. A drug called sacituzumab govitecan (SG) has been approved for use in other types of cancers.
- Conditions
- Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma, Recurrent Epithelial Cervical Carcinoma
- Trial name
- NCT06865677
- Testing
- Sacituzumab Govitecan, EKG, Brain MRI
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)